MolGen announced last Wednesday that it has acquired Dutch automation company Synchron Instrumenten BV, also known as Synchron Lab Automation.
Image Credit: MolGen
With this acquisition, MolGen will expand its existing portfolio and its ability to build high-end automation solutions for DNA/RNA purification, library preparation and NGS setup to support MolGen’s reagent business. The custom liquid handling platforms and rapid prototyping capabilities of Synchron will be used to further expand MolGen’s automation portfolio.
This acquisition will enable MolGen to more efficiently build automation solutions, to enable our customers globally; to meet the challenges in terms of the increasing demand of sample throughput and cost efficiency.”
Niels Kruize, CEO, MolGen
MolGen and Synchron have already co-developed several automated solutions in recent years, ranging from systems for sample transfer from capped sample tubes to microtitre plates, to a platform for ultra high throughput DNA/RNA purification, called the DNA Factory. This system provides serial automation that enables laboratories to scale up DNA/RNA purification, PCR setup and library preparation for NGS applications.
Derk Wilten will continue as Managing Director of Synchron and all other contacts at Synchron remain unchanged.
“Synchron will be enabled to grow and reach more customers globally, via MolGens commercial, application and service team. Combining our hard- and software solutions with MolGen’s reagents will enable us to offer novel solutions and entire workflows that are in strong demand in high throughput genomics labs,” says Derk Wilten, Managing Director of Synchron.